Ignite Creation Date:
2024-05-06 @ 7:14 PM
Last Modification Date:
2024-10-26 @ 3:03 PM
Study NCT ID:
NCT05945927
Status:
RECRUITING
Last Update Posted:
2024-06-21
First Post:
2023-06-29
Brief Title:
A Study to Evaluate the Safety and Effectiveness of Trastuzumab Emtansine T-DM1 as Therapy in Chinese Participants With HER2 Positive Advanced Breast Cancer
Sponsor:
Hoffmann-La Roche
Organization:
Hoffmann-La Roche
Study Overview
Official Title:
An Observational Study to Evaluate the Safety and Effectiveness of Trastuzumab Emtansine T-DM1 as Second- or Later-Line Therapy in Chinese Patients With HER2 Positive Advanced Breast Cancer
Status:
RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is a post-marketing observational multicenter prospective study It will investigate the the safety and effectiveness of T-DM1 in the Chinese population in real-world clinical practice
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None